Research in Allergic Rhinitis
Omalizumab reduces the risk of anaphylaxis in patients who are receiving immunotherapy. SLIT has been suggested to bring about a significant reduction in symptoms.
New and better new immune-based therapies are being searched for. Drugs called Anti–immunoglobulin E Antibodies (Omalizumab) have been evaluated in the treatment of Seasonal Allergic Rhinitis (SAR). Omalizumab reduces the risk of anaphylaxis in patients who are receiving immunotherapy. It is however expensive. Novel Forms of Immunotherapy that are associated with lower risk for fatal body reactions (anaphylaxis) are also being developed. Sublingually administered allergen immunotherapy (SLIT) has been suggested to bring about a significant reduction in symptom and medication scores in patients with
- Cecil Medicine, 23rd Ed.
- The Merck Manual, 18th Ed.
Please use one of the following formats to cite this article in your essay, paper or report:
Dr. Nithin Jayan. (2014, June 03). Research in Allergic Rhinitis. Medindia. Retrieved on Oct 04, 2023 from https://www.medindia.net/patients/patientinfo/allergic-rhinitis-research.htm.
Dr. Nithin Jayan. "Research in Allergic Rhinitis". Medindia. Oct 04, 2023. <https://www.medindia.net/patients/patientinfo/allergic-rhinitis-research.htm>.
Dr. Nithin Jayan. "Research in Allergic Rhinitis". Medindia. https://www.medindia.net/patients/patientinfo/allergic-rhinitis-research.htm. (accessed Oct 04, 2023).
Dr. Nithin Jayan. 2014. Research in Allergic Rhinitis. Medindia, viewed Oct 04, 2023, https://www.medindia.net/patients/patientinfo/allergic-rhinitis-research.htm.
Do you wish to consult an Otolaryngologist / ENT Specialist for your problem? Ask your question
4 years experience
21 years experience
20 years experience